Pulling back from the brink
The US healthcare reform bill raises as many questions as it answers for Big Pharma
For the pharmaceutical industry, the bill is a bit of a mixed bag, although the general impression at the moment is that manufacturers will gain more than they lose. At the very least some of the uncertainty affecting the sector has been removed.
With an extra 32 million potential patients entering the market, the number of prescriptions is bound to rise, but this is likely to be offset by the imposition of higher discounts and rebates. And with a number of significant patents due to expire in 2011, a short-term downturn for the industry seems inevitable, although these negative effects should be offset by rising revenues from increased drug consumption by around 2015, according to Datamonitor.
But as drug costs rise, the US government is bound to want to make sure it is getting the best possible value for its money and will increase its involvement in the healthcare sector. While this will be good news for the manufacturers of generic medicines, the authorities will need to try to avoid some of the less palatable aspects of the UK system – trying to define ‘quality of life’, and the notorious ‘postcode prescribing’.
From a European point of view, the US system was patently unfair and long overdue for reform. However imperfect the various healthcare regimes are in the EU, there is at least always a safety net to ensure that every citizen is entitled to receive at least a basic level of service.
It is hard to comprehend the strenuous efforts mounted – both by opposition politicians and the general public – to defend a system that excludes more than 32 million people and where a patient who survives cancer is essentially ruled out of any future treatment by a massive rise in premiums that put them beyond the reach of those on an average income. Shockingly, half of all personal bankruptcies in the US are at least partially due to medical costs.
The reforms may still be flawed, but at least those outside the current system dangling by a thin rope and staring into the abyss have been thrown a lifeline.
Hilary Ayshford
Editor
You may also like
Trending Articles
You may also like
Regulatory
UK REACH ATRm: CBA welcomes progress but warns of significant hurdles ahead
The Chemical Business Association has acknowledged long-awaited movement on the UK REACH Alternative Transitional Registration model following DEFRA's consultation response, but cautioned that cost burdens likely running into hundreds of millions of pounds
Regulatory
Lonza Nominates Stephen Fry as Independent Board Member
Basel, Switzerland, 31 March 2026 – The Lonza Board of Directors today announced the nomination of Stephen Fry as an Independent Member of the Board. Subject to his election at the Lonza Group Annual General Meeting (AGM) in May 2026, Stephen will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committeex
Research & Development
Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform
Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing